# Executive Summary: Precision Medicine MCP System

## Overview

The **Precision Medicine MCP System** is an AI-orchestrated platform for precision oncology that enables **multi-modal synthesis** — integrating clinical, genomic, multi-omics, spatial transcriptomics, and imaging data in ways manual workflows cannot achieve at scale. All tools are accessible via natural language (no coding required). Every AI-generated result requires **clinician APPROVE/REVISE/REJECT** before clinical use — the system assists clinicians, never replaces them.

Built on the Model Context Protocol (MCP) with HIPAA-compliant architecture (Safe Harbor de-identification, 10-year immutable audit trails, VPC isolation). Reduces production analysis from an estimated 40 hours to 2-5 hours.

**Status:** POC validated on synthetic data; majority of servers are production-ready (not mocked); next step is deployment to hospital pilot

---

## Clinical Safety & Governance

> **This is a clinical decision support tool. AI assists — clinicians decide.**

| Safety Guarantee | Details |
|-----------------|---------|
| **Clinician-in-the-Loop** | Every AI-generated report requires clinician **APPROVE / REVISE / REJECT** before clinical use |
| **HIPAA Safe Harbor** | All 18 PHI identifiers removed; 10-year immutable audit trails; VPC isolation |
| **Regulatory Posture** | Designed as CDS tool exempt from FDA device clearance under 21st Century Cures Act (four criteria satisfied — confirm with regulatory counsel) |
| **Bias Auditing** | Quarterly audits aligned with FDA AI/ML SaMD guidance; fairness metrics tracked across demographics |
| **Full Traceability** | Every AI routing decision, tool call, parameter, and result is logged and visualizable |

> **When the system is wrong:** Bayesian uncertainty quantification flags low-confidence results. Bias auditing identifies population-specific limitations. Ultimate clinical responsibility rests with the treating physician.

---

## System Architecture

```mermaid
graph LR
    subgraph Users["Users"]
        U[Clinicians<br/>Researchers<br/>Bioinformaticians]
    end

    subgraph AI["AI Orchestration"]
        LLM[Claude or Gemini]
    end

    subgraph Servers["MCP Servers & Tools"]
        direction TB
        IMAGING["Imaging & Cell Analysis<br/>deepcell · cell-classify · openimagedata<br/>━━━━━━━━━━━━━━━━━━━<br/>📁 H&E · MxIF"]
        GENOMICS["Genomics & Omics<br/>fgbio · multiomics · spatialtools · perturbation · mocktcga · genomic-results<br/>━━━━━━━━━━━━━━━━━━━<br/>📁 VCF/FASTQ · RNA/Protein/Phospho · Visium · Somatic/CNV/HRD"]
        CLINICAL["Clinical<br/>epic · mockepic · patient-report<br/>━━━━━━━━━━━━━━━━━━━<br/>📁 FHIR"]
        WORKFLOW["Workflow & ML<br/>quantum-celltype-fidelity<br/>━━━━━━━━━━━━━━━━━━━<br/>📁 Cross-modality"]
    end

    subgraph Output["Outputs"]
        O[Treatment Recommendations<br/>Visualizations & Reports]
    end

    Users --> AI
    AI --> Servers
    Servers --> Output

    style Users fill:#e1f5ff,stroke:#0288d1,stroke-width:2px
    style AI fill:#fff3cd,stroke:#ffc107,stroke-width:2px
    style Servers fill:#d4edda,stroke:#28a745,stroke-width:2px
    style Output fill:#d1ecf1,stroke:#0c5460,stroke-width:2px
```

**Key Points:**
- **AI Orchestration**: Claude + Gemini 3 AI coordinates multiple MCP servers via natural language  
- **Specialized Tools**: Bioinformatics tools across genomics, multi-omics, spatial, imaging, cell segmentation, perturbation prediction, quantum computing, genomic results, and patient reports with Bayesian uncertainty quantification
- **Production Ready**: Most servers deployed to Cloud Run; 1 local-only (Epic FHIR), 2 mock (mockepic by design, mocktcga synthetic)
- **Cost Efficient**: Low per-analysis compute cost; significant per-patient cost reduction vs. traditional methods (see Financial Summary and [Cost Analysis](../reference/shared/cost-analysis.md))

---

## Value Proposition

**Novel Capabilities (what becomes possible):**
- **Multi-modal synthesis** — Correlate spatial gene expression with protein phosphorylation and genomic variants in a single analysis, not separate silos
- **Cross-modality integration** — Link spatial cell-type composition to treatment response using clinical data — previously requiring weeks of manual work
- **Accessible bioinformatics** — Complex tools (spatial autocorrelation, perturbation prediction, quantum cell-type fidelity) accessible via natural language, no coding required
- **Automated cross-referencing** — Patient results correlated with PubMed, bioRxiv, ClinicalTrials.gov, and TCGA cohorts in real-time

**For Research Hospitals:**
- Enables community hospitals and mid-size cancer centers to offer precision oncology programs that previously required large academic medical center teams
- Reduce minimum viable precision medicine team from ~10 FTEs to ~3 (2 clinicians + 1-2 bioinformaticians)
- Reduce multi-omics analysis time from weeks to hours
- Significant projected savings per patient vs. traditional manual analysis ([Value Proposition](../reference/shared/value-proposition.md))
- Scalable from 100-patient pilot to institutional biobank

**For Bioinformaticians:**
- Unified platform for bioinformatics tools across multiple MCP servers
- Natural language interface reduces manual pipeline coding (bioinformatician oversight still required for clinical interpretation)
- Reproducible workflows with automated orchestration
- Bayesian uncertainty quantification for confident clinical decisions
- Domain-organized Jupyter notebooks (imaging, genomics, clinical, workflow/ML) for interactive analysis

---

## Financial Summary

Projected payback within first few patients analyzed. Significant annual ROI at both pilot (100-patient) and production (500-patient) scale.

Per-patient costs represent a significant reduction vs. traditional methods (compute + personnel). Savings estimates are modeled, not yet validated in a clinical pilot (see Validation Status below).

> **Full cost analysis:** See [Cost Analysis](../reference/shared/cost-analysis.md) for detailed breakdowns and [ROI Analysis](ROI_ANALYSIS.md) for investment tier returns.

---

## Technical Capabilities

**MCP Servers and Tools** ([Server Registry](../reference/shared/server-registry.md)): 17 custom servers (97 tools) — 15 production-ready, 2 mock. Plus 6 external servers (46 tools) for literature, trials, and genomics data ([details](../for-researchers/CONNECT_EXTERNAL_MCP.md)).

**Data Integration:**
- Clinical: Epic FHIR with de-identification
- Genomic: WES/WGS, somatic variants, CNV, germline risk
- Spatial: 10x Visium, cell type deconvolution, microenvironment analysis
- Imaging: H&E histopathology, multiplex immunofluorescence
- External: Real TCGA via cBioPortal, literature via PubMed/bioRxiv, trials via ClinicalTrials.gov ([external connectors](../for-researchers/CONNECT_EXTERNAL_MCP.md))

---

## Hospital Deployment

### HIPAA Compliance
- ✅ Built-in de-identification (HIPAA Safe Harbor method)
- ✅ 10-year audit log retention
- ✅ VPC isolation, encrypted secrets, Azure AD SSO
- ⚠️ Epic FHIR integration (mcp-epic) runs local-only, not on Cloud Run — PHI never leaves the hospital network. This is by design but requires separate infrastructure from the other servers.

> **Full HIPAA documentation:** See [HIPAA Summary](../reference/shared/hipaa-summary.md) and [for-hospitals compliance docs](../for-hospitals/compliance/hipaa.md).

### Deployment Timeline (6 Months)
- **Month 1-2**: Infrastructure setup, Azure AD SSO, core 3 servers, Epic FHIR integration
- **Month 3-4**: All servers deployed, 10-20 test patients, user training, security audit
- **Month 5-6**: Monitoring/alerting, compliance validation, knowledge transfer, production launch (100 patients)

### Requirements

**Prerequisites (must exist before the 6-month timeline starts):**
- Existing HIPAA-compliant GCP organization (if not in place, add 3-6 months)
- Azure AD federation configured for SSO
- Epic integration team available for FHIR API access

**Deployment resources:**
- Dedicated GCP project (modest monthly infrastructure cost — see [Cost Analysis](../reference/shared/cost-analysis.md))
- Hospital IT, Azure AD admin, Epic integration team coordination
- 5 pilot users: 2 clinicians, 3 bioinformaticians

---

## Risk Assessment

- **Technical Risks:** LOW — Auto-scaling, fallback to mock data, comprehensive error handling
- **Financial Risks:** LOW — Daily monitoring, cost alerts at 80%, model optimization (Haiku)
- **Compliance Risks:** LOW — Built-in de-identification, audit logging, VPC isolation, encrypted secrets
- **AI Vendor Dependency:** MEDIUM — The orchestration layer depends on commercial APIs from Anthropic (Claude) and Google (Gemini). Mitigations: dual-provider support (if one changes pricing or deprecates models, the other provides fallback), MCP server layer is provider-agnostic (servers work with any LLM that supports tool calling), and no PHI is sent to AI providers (only de-identified data)
- **Adoption Risks:** MEDIUM-HIGH — Multi-stakeholder hospital coordination (IT, Azure AD admins, Epic team, clinicians, bioinformaticians) is historically the top failure mode for health IT projects. Mitigated through phased rollout, Streamlit UI for clinicians, Jupyter for bioinformaticians, and dedicated training sessions
- **Overall Risk:** MEDIUM — Technical and compliance risks well-mitigated; adoption and vendor dependency require active management

---

## Ethics & Algorithmic Fairness

The system incorporates comprehensive bias detection aligned with FDA AI/ML SaMD guidance, AMA ethics standards, and NIH All of Us diversity requirements.

**Bias Auditing Framework:**
- **Quarterly audits** of production workflows with 10-year report retention
- **Automated tools**: `bias_detection.py` (600 lines), `audit_bias.py` (550 lines)
- **Risk thresholds**: <5% representation = CRITICAL, >20% fairness disparity = CRITICAL

**PatientOne Audit Example:**
- Risk Level: MEDIUM (acceptable with mitigations)
- Finding: BRCA databases Euro-centric (70% European) → Mitigation: Flag variants with <5 studies, reduce confidence 30%
- Fairness metrics: Demographic parity, equalized odds, calibration all ACCEPTABLE (<10% disparity)

**Diverse Reference Datasets:**
- Genomics: gnomAD (43% European, 21% African, 14% Latino), All of Us (80% underrepresented)
- Spatial: Human Cell Atlas (35M+ cells, global diversity), TOPMed (180K+ genomes)

**Impact:** Addresses 73% patient concern about AI bias, meets FDA/IRB expectations for systematic bias evaluation

---

## Validation Status

**What has been validated:**
- End-to-end workflow on synthetic data (PatientOne: PAT001-OVC-2025, 100% synthetic)
- Majority of MCP servers have (passing) automated test suites 
- Cloud Run deployment and scaling on GCP
- Dual-provider orchestration (Claude and Gemini both calling MCP tools)
- DRY_RUN mode for safe testing without real data or costly compute

**What has NOT yet been validated:**
- Real patient data in a clinical setting (no pilot with actual patients to date)
- Cost savings estimates ([Value Proposition](../reference/shared/value-proposition.md)) — modeled from traditional workflow comparisons, not measured in production
- Clinical concordance — AI-generated treatment recommendations have not been compared against oncologist decisions in a prospective study
- The "41% error reduction" cited in Competitive Advantages is an estimate based on reproducibility improvements from automated vs. manual pipelines, not a clinical trial result

**Validation roadmap (during pilot):**
- Month 3-4: Run 10-20 de-identified patients through the system alongside standard clinical workflow
- Month 5-6: Compare AI-assisted analysis time, cost, and concordance with clinician-generated reports
- Post-pilot: Publish validation results; establish baseline metrics for production monitoring

---

## Success Metrics

**Technical Performance:**
- System uptime: >99.5% | Query response: <30s | Error rate: <1% | De-identification: 100%

**Business Impact:**
- Users: 5 (pilot) → 20 (production)
- Patients: 100 (pilot) → 500 (Year 1)
- Cost: Significant per-patient cost reduction vs. traditional methods  

**Research Outcomes:**
- Analysis results supporting 2+ manuscripts
- AI-assisted precision therapy selection
- Unified clinical-genomic-spatial-imaging view

---

## Competitive Advantages

**vs. Traditional Pipelines:** Multi-modal synthesis across 5 data types in one workflow, natural language interface (no coding), built-in HIPAA compliance, 8-20x faster (estimated)

**vs. Commercial Platforms:** Open-source (Apache 2.0), hospital-controlled data — no vendor lock-in on the server layer, multi-modal integration, 75-90% compute cost reduction

**vs. Manual Integration:** Cross-modality insights previously infeasible at scale, reproducible workflows, automated harmonization, reduced minimum team size

---


## Conclusion

The Precision Medicine MCP System delivers:
- **Clinician authority preserved**: Every AI result requires APPROVE/REVISE/REJECT — no autonomous clinical decisions
- **HIPAA-compliant architecture** with de-identification, 10-year audit trails, bias auditing, and VPC isolation
- **Novel multi-modal synthesis**: Cross-modality insights (genomic + spatial + proteomic + clinical) previously infeasible at scale
- **Team compression**: Reduces minimum precision medicine team from ~10 FTEs to ~3, making precision oncology feasible for mid-size hospitals
- **6-month deployment** timeline from approval to production (assumes GCP and Azure AD prerequisites in place)
- **Strong projected ROI**: Significant modeled savings per patient, payback in first few patients ([Value Proposition](../reference/shared/value-proposition.md))

**Next step:** Fund a 6-month pilot at a single site to validate cost savings, clinical concordance, and adoption feasibility with real (de-identified) patient data.

---

**Document Version:** 1.6
**Date:** 2026-02-24
**Status:** Ready for Funding Review
**Contact:** Lynn Langit
